B. Riley reiterated their buy rating on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Thursday morning, Marketbeat.com reports. B. Riley currently has a $5.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $10.00. B. Riley also issued estimates for Evoke Pharma’s FY2022 earnings at $1.40 EPS.
A number of other brokerages have also recently weighed in on EVOK. ValuEngine cut shares of Evoke Pharma from a sell rating to a strong sell rating in a research report on Friday, December 1st. Zacks Investment Research upgraded shares of Evoke Pharma from a sell rating to a hold rating in a research report on Tuesday, February 6th. Finally, HC Wainwright set a $9.00 price target on shares of Evoke Pharma and gave the company a buy rating in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $7.66.
Shares of Evoke Pharma (NASDAQ EVOK) traded down $0.10 on Thursday, hitting $1.98. 139,177 shares of the company’s stock were exchanged, compared to its average volume of 122,638. Evoke Pharma has a 1-year low of $1.85 and a 1-year high of $4.09.
Several hedge funds have recently made changes to their positions in EVOK. Creative Planning acquired a new position in shares of Evoke Pharma in the fourth quarter valued at approximately $226,000. B. Riley Financial Inc. acquired a new position in shares of Evoke Pharma in the fourth quarter valued at approximately $249,000. 683 Capital Management LLC acquired a new position in shares of Evoke Pharma in the fourth quarter valued at approximately $258,000. Deutsche Bank AG acquired a new position in shares of Evoke Pharma in the fourth quarter valued at approximately $452,000. Finally, Vanguard Group Inc. grew its holdings in shares of Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 68,544 shares in the last quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Evoke Pharma’s (EVOK) Buy Rating Reiterated at B. Riley” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/11/evoke-pharmas-evok-buy-rating-reiterated-at-b-riley.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.